Distinct HDAC6 inhibition can also sensitize cancer cells to SAHA treatment because the HDAC6-selective inhibitor tubacin was able to increase apoptosis and DNA damage induced by SAHA in LNCaP prostate tumor cells [42]. This evidence concerns the gene HDAC6 and cancer.